Three-dimensional models of neurotransmitter transporters and their interactions with cocaine and S-citalopram

References

• Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, Iwata S. Structure and mechanism of the lactose permease of Escherichia coli. Science 2003; 301: 610–615
   PubMed Web of Science ®Google Scholar
• Akunne HC, de Costa BR, Jacobson AE, Rice KC, Rothman RB. [3H]Cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine. Neurochem Res 1992; 17: 1275–1283
   PubMedGoogle Scholar
• Bardo MT. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 1998; 12: 37–67
   PubMed Web of Science ®Google Scholar
• Barker EL, Blakely RD. Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. Psychopharmacology: The fourth generation of progress, FE Bloom, DJ Kupfer. Raven Press, New York 1995; 321–334
   Google Scholar
• Barker EL, Moore KR, Rakhshan F, Blakely RD. Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci 1999; 19: 4705–4717
   PubMedGoogle Scholar
• Barker EL, Perlman MA, Adkins EM, Houlihan WJ, Pristupa ZB, Niznik HB, Blakely RD. High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J Biol Chem 1998; 273: 19459–19468
   PubMedGoogle Scholar
• Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38: 1083–1152
   PubMed Web of Science ®Google Scholar
• Boja JW, Vaughan R, Patel A, Shaya EK, Kuhar MJ. The dopamine transporter. Dopamine receptors and transporters, HB Niznik. Marcel Dekker, New York 1994; 611–644
   Google Scholar
• Chalmers AF. What is this thing called science?. Open University Press, Buckingham 2002
   Google Scholar
• Chang AS, Starnes DM, Chang SM. Possible existence of quaternary structure in the high-affinity serotonin transport complex. Biochem Biophys Res Commun 1998; 249: 416–421
   PubMedGoogle Scholar
• Chang G, Roth CB. Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 2001; 293: 1793–1800
   PubMed Web of Science ®Google Scholar
• Chen JG, Sachpatzidis A, Rudnick G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J Biol Chem 1997; 272: 28321–28327
   PubMedGoogle Scholar
• Dahl SG, Edvardsen O, Sylte I. Molecular dynamics of dopamine at the D2 receptor. Proc Natl Acad Sci USA 1991; 88: 8111–8115
   PubMed Web of Science ®Google Scholar
• Dahl SG, Sylte I, Ravna AW. Structures and models of transporter proteins. J Pharmacol Exp Ther 2004; 309: 853–860
   PubMedGoogle Scholar
• Gerchman Y, Olami Y, Rimon A, Taglicht D, Schuldiner S, Padan E. Histidine-226 is part of the pH sensor of NhaA, a Na+/H+ antiporter in Escherichia coli. Proc Natl Acad Sci USA 1993; 90: 1212–1216
   PubMedGoogle Scholar
• Gerchman Y, Rimon A, Padan E. A pH-dependent conformational change of NhaA Na(+)/H(+) antiporter of Escherichia coli involves loop VIII-IX, plays a role in the pH response of the protein, and is maintained by the pure protein in dodecyl maltoside. J Biol Chem 1999; 274: 24617–24624
   PubMedGoogle Scholar
• Gerchman Y, Rimon A, Venturi M, Padan E. Oligomerization of NhaA, the Na + /H+ antiporter of Escherichia coli in the membrane and its functional and structural consequences. Biochemistry 2001; 40: 3403–3412
   PubMedGoogle Scholar
• Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 1992; 42: 383–390
   PubMed Web of Science ®Google Scholar
• Hall FS, Li XF, Sora I, Xu F, Caron M, Lesch KP, Murphy DL, Uhl GR. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience 2002; 115: 153–161
   PubMed Web of Science ®Google Scholar
• Hastrup H, Karlin A, Javitch JA. Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc Natl Acad Sci USA 2001; 98: 10055–10060
   PubMedGoogle Scholar
• Hibert MF, Trumpp-Kallmeyer S, Bruinvels A, Hoflack J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol Pharmacol 1991; 40: 8–15
   PubMed Web of Science ®Google Scholar
• Horschitz S, Hummerich R, Schloss P. Structure, function and regulation of the 5-hydroxytryptamine (serotonin) transporter. Biochem Soc Trans 2001; 29: 728–732
   PubMed Web of Science ®Google Scholar
• Huang Y, Lemieux MJ, Song J, Auer M, Wang DN. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 2003; 301: 616–620
   PubMed Web of Science ®Google Scholar
• Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9(Suppl 1)19–26
   PubMed Web of Science ®Google Scholar
• Inoue H, Noumi T, Tsuchiya T, Kanazawa H. Essential aspartic acid residues, Asp-133, Asp-163 and Asp-164, in the transmembrane helices of a Na+/H+ antiporter (NhaA) from Escherichia coli. FEBS Lett 1995; 363: 264–268
   PubMedGoogle Scholar
• Jess U, El Far O, Kirsch J, Betz H. Interaction of the C-terminal region of the rat serotonin transporter with MacMARCKS modulates 5-HT uptake regulation by protein kinase C. Biochem Biophys Res Commun 2002; 294: 272–279
   PubMedGoogle Scholar
• Kaback HR, Wu J. From membrane to molecule to the third amino acid from the left with a membrane transport protein. Q Rev Biophys 1997; 30: 333–364
   PubMed Web of Science ®Google Scholar
• Kilic F, Rudnick G. Oligomerization of serotonin transporter and its functional consequences. Proc Natl Acad Sci USA 2000; 97: 3106–3111
   PubMedGoogle Scholar
• Kitayama S, Morita K, Dohi T, Wang JB, Davis SC, Uhl GR. Dissection of dopamine and cocaine binding sites on the rat dopamine transporter expressed in COS cells. Ann NY Acad Sci 1996; 801: 388–393
   PubMedGoogle Scholar
• Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 1992; 89: 7782–7785
   PubMed Web of Science ®Google Scholar
• Kuroda T, Shimamoto T, Mizushima T, Tsuchiya T. Mutational analysis of amiloride sensitivity of the NhaA Na+/H+ antiporter from Vibrio parahaemolyticus. J Bacteriol 1997; 179: 7600–7602
   PubMedGoogle Scholar
• Lee SH, Chang MY, Lee KH, Park BS, Lee YS, Chin HR. Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane binding of dopamine transporter. Mol Pharmacol 2000; 57: 883–889
   PubMedGoogle Scholar
• Lin J, Thompson DS. Treating premenstrual dysphoric disorder using serotonin agents. J Womens Health Gend Based Med 2001; 10: 745–750
   PubMedGoogle Scholar
• Lin Z, Wang W, Kopajtic T, Revay RS, Uhl GR. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol Pharmacol 1999; 56: 434–447
   PubMedGoogle Scholar
• Lin Z, Zhang PW, Zhu X, Melgari JM, Huff R, Spieldoch RL, Uhl GR. Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem 2003; 278: 20162–20170
   PubMedGoogle Scholar
• Locher KP, Lee AT, Rees DC. The E. coli BtuCD structure: a framework for ABC transporter architecture and mechanism. Science 2002; 296: 1091–1098
   PubMed Web of Science ®Google Scholar
• Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001; 35: 5–49
   PubMedGoogle Scholar
• Mitsuhata C, Kitayama S, Morita K, Vandenbergh D, Uhl GR, Dohi T. Tyrosine-533 of rat dopamine transporter: involvement in interactions with 1-methyl-4-phenylpyridinium and cocaine. Brain Res Mol Brain Res 1998; 56: 84–88
   PubMedGoogle Scholar
• Murakami S, Nakashima R, Yamashita E, Yamaguchi A. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 2002; 419: 587–593
   PubMed Web of Science ®Google Scholar
• Noumi T, Inoue H, Sakurai T, Tsuchiya T, Kanazawa H. Identification and characterization of functional residues in a Na+/H+ antiporter (NhaA) from Escherichia coli by random mutagenesis. J Biochem (Tokyo) 1997; 121: 661–670
   PubMedGoogle Scholar
• Olami Y, Rimon A, Gerchman Y, Rothman A, Padan E. Histidine 225, a residue of the NhaA-Na+/H+ antiporter of Escherichia coli is exposed and faces the cell exterior. J Biol Chem 1997; 272: 1761–1768
   Google Scholar
• Padan E, Gerchman Y, Rimon A, Rothman A, Dover N, Carmel-Harel O. The molecular mechanism of regulation of the NhaA Na+/H+ antiporter of Escherichia coli, a key transporter in the adaptation to Na+ and H+. Novartis Found Symp 1999; 221: 183–196
   PubMedGoogle Scholar
• Padan E, Schuldiner S. Na+/H+ antiporters, molecular devices that couple the Na+ and H+ circulation in cells. J Bioenerg Biomembr 1993; 25: 647–669
   PubMedGoogle Scholar
• Padan E, Schuldiner S. Molecular physiology of the Na+/H+ antiporter in Escherichia coli. J Exp Biol 1994; 196: 443–456
   PubMedGoogle Scholar
• Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289: 739–745
   PubMed Web of Science ®Google Scholar
• Pinner E, Padan E, Schuldiner S. Amiloride and harmaline are potent inhibitors of NhaB, a Na+/H+ antiporter from Escherichia coli. FEBS Lett 1995; 365: 18–22
   PubMedGoogle Scholar
• Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD. Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 1993; 90: 2542–2546
   PubMed Web of Science ®Google Scholar
• Ravna AW, Sylte I, Dahl SG. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters. J Pharmacol Exp Ther 2003a; 307: 34–41
   PubMedGoogle Scholar
• Ravna AW, Sylte I, Dahl SG. Molecular model of the Echerichia coli Na+/H+ antiporter NhaA. Receptors Channels 2001; 7: 319–328
   PubMedGoogle Scholar
• Ravna AW, Sylte I, Dahl SG. Molecular model of the neural dopamine transporter. J Comput Aided Mol Des 2003b; 17: 367–382
   PubMedGoogle Scholar
• Ravna AW, Sylte I, Kristiansen K, Dahl SG. Putative drug binding conformations of monoamine transporters. Bioorg Med Chem 2006; 14: 666–675
   PubMedGoogle Scholar
• Reizer J, Reizer A, Saier MH, Jr. A functional superfamily of sodium/solute symporters. Biochim Biophys Acta 1994; 1197: 133–166
   PubMed Web of Science ®Google Scholar
• Rimon A, Gerchman Y, Kariv Z, Padan E. A point mutation (G338S) and its suppressor mutations affect both the pH response of the NhaA-Na+/H+ antiporter as well as the growth phenotype of Escherichia coli. J Biol Chem 1998; 273: 26470–26476
   PubMedGoogle Scholar
• Rothman A, Padan E, Schuldiner S. Topological analysis of NhaA, a Na+/H+ antiporter from Escherichia coli. J Biol Chem 1996; 271: 32288–32292
   PubMedGoogle Scholar
• Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1965; 122: 509–522
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215–235
   PubMed Web of Science ®Google Scholar
• Sur C, Betz H, Schloss P. Distinct effects of imipramine on 5-hydroxytryptamine uptake mediated by the recombinant rat serotonin transporter SERT1. J Neurochem 1998; 70: 2545–2553
   PubMedGoogle Scholar
• Taglicht D, Padan E, Schuldiner S. Overproduction and purification of a functional Na+/H+ antiporter coded by nhaA (ant) from Escherichia coli. J Biol Chem 1991; 266: 11289–11294
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249–258
   PubMed Web of Science ®Google Scholar
• Torres GE, Carneiro A, Seamans K, Fiorentini C, Sweeney A, Yao WD, Caron MG. Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem 2003; 278: 2731–2739
   PubMedGoogle Scholar
• Toyoshima C, Nakasako M, Nomura H, Ogawa H. Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature 2000; 405: 647–655
   PubMed Web of Science ®Google Scholar
• Uhl G, Lin Z, Metzger T, Dar DE. Dopamine transporter mutants, small molecules, and approaches to cocaine antagonist/dopamine transporter disinhibitor development. Methods Enzymol 1998; 296: 456–465
   PubMedGoogle Scholar
• Uhl GR, Hall FS, Sora I. Cocaine, reward, movement and monoamine transporters. Mol Psychiatry 2002; 7: 21–26
   PubMed Web of Science ®Google Scholar
• Williams KA. Three-dimensional structure of the ion-coupled transport protein NhaA. Nature 2000; 403: 112–115
   PubMed Web of Science ®Google Scholar